{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-24-000015","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.938337+00:00","generated_at":"2026-06-05T11:12:05.051461+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Supernus Q4 rev $164.3M, Qelbree +97% YoY; FY23 GAAP op loss $5.3M, non-GAAP op earnings $125.1M","bullets":["Q4 2023 total revenues $164.3M (GAAP); full year 2023 total revenues $607.5M, down 9% YoY.","Qelbree net sales Q4 $46.4M (+97% YoY), full year $140.2M (+129%); GOCOVRI Q4 $32.0M (+10%), full year $119.6M (+15%).","Full year 2023 GAAP operating loss $(5.3)M; non-GAAP operating earnings $125.1M. GAAP net earnings $1.3M ($0.02 diluted EPS).","FY2024 guidance: total revenues $580-$620M; non-GAAP operating earnings $80-$110M; expects generic erosion of Trokendi XR/Oxtellar XR from Sep 2024.","Pipeline: SPN-830 PDUFA April 5, 2024; Phase IIb SPN-820 data H1 2025; interim Phase IIa SPN-817 data May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-24-000015","json":"https://secwatch.observer/filing/0001356576-24-000015.json","markdown":"https://secwatch.observer/filing/0001356576-24-000015.md","text":"https://secwatch.observer/filing/0001356576-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/0001356576-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/supn-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:12:05.051461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66c65c6ae6ba077549ed8ce41b4ee92b12023854","claim":"SUPERNUS PHARMACEUTICALS, INC. reported Full year 2023 results: revenue Total revenues (GAAP) of $607.5 million.","evidence_excerpt":"For the full year ended December 31, 2023, total revenues and total net product sales were $607.5 million and $573.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/0001356576-24-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year 2023"},{"label":"Revenue","value":"Total revenues (GAAP) of $607.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bcbaa12713f01490491a0c515e0fc5a68cafee57","claim":"SUPERNUS PHARMACEUTICALS, INC. reported Fourth quarter 2023 results: revenue Total revenues (GAAP) of $164.3 million.","evidence_excerpt":"For the three months ended December 31, 2023, total revenues and total net product sales (GAAP) were $164.3 million and $156.0 million, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/0001356576-24-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter 2023"},{"label":"Revenue","value":"Total revenues (GAAP) of $164.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}